A tiny contaminant with an outsized physiological effect
Medetomidine is not a new drug in pharmacological terms. It is an alpha-2 adrenergic agonist developed for veterinary sedation and analgesia, especially in cats and dogs. What concerns toxicologists is its potency. The UK Advisory Council on the Misuse of Drugs has said medetomidine is likely to be around 200 times more potent than xylazine at alpha-2 receptors, meaning very small quantities can materially change the effect of an unregulated dose of heroin or fentanyl.
Its effects can also be difficult to predict outside a controlled veterinary setting. Peripheral vasoconstriction can initially drive blood pressure upward, while central nervous system effects cause deep sedation and a pronounced slowing of the heart. Blood pressure can later fall. When medetomidine is combined with opioids or benzodiazepines, loss of consciousness, breathing problems and cardiovascular instability can overlap in ways that are difficult for both users and first responders to recognise.
“The sedative effects of drugs containing an opioid and medetomidine may not fully respond to naloxone.” — UK Advisory Council on the Misuse of Drugs

















